Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study

Oral Oncology

Volumn 47, Issue 3, 2011, Pages 185-190

  Ripamonti, Carla Ida ^a   Cislaghi, Enrico ^a   Mariani, Luigi ^a   Maniezzo, Massimo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bisphosphonates related osteonecrosis of the jaw (BONJ); Curative treatment; Oil suspension of medical O3 therapy

Indexed keywords

AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; OZONE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; JAW OSTEONECROSIS; MALE; OSSIFICATION; OZONE THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAFETY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OILS; OSTEONECROSIS; OZONE; PROSPECTIVE STUDIES; SUSPENSIONS; TREATMENT OUTCOME;

EID: 79952281080     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.01.002     Document Type: Article

References (45)

1. R.E. Coleman Skeletal complications of malignancy Cancer 80 Suppl. 8 1997 1588 1594 (Pubitemid 27444031)
2. F. Fulfaro, A. Casuccio, C. Ticozzi, and C. Ripamonti The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 3 1998 157 169 (Pubitemid 29052273)
3. J.J. Body, I.J. Diel, M.R. Lichinitser, E.D. Kreuser, W. Dornoff, and V.A. Gorbunova Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 9 2003 1399 1405 (Pubitemid 37185286)
4. N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, and Y. Iino Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 15 2005 3314 3321
5. A. Lipton, R.L. Theriault, G.N. Hortobagyi, J. Simeone, R.D. Knight, and K. Mellars Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials Cancer 88 5 2000 1082 1090 (Pubitemid 30127670)
6. A. Lipton, M. Zheng, and J. Seaman Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 5 2003 962 969 (Pubitemid 37022096)
7. E.V. McCloskey, I.C. MacLennan, M.T. Drayson, C. Chapman, J. Dunn, and J.A. Kanis A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on leukaemia in adults Br J Haematol 100 2 1998 317 325 (Pubitemid 28131063)
8. A.H. Paterson, T.J. Powles, J.A. Kanis, E. McCloskey, J. Hanson, and S. Ashley Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 1 1993 59 65 (Pubitemid 23059975)
9. L.S. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh, and M. Krzakowski Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group J Clin Oncol 21 16 2003 3150 3157 (Pubitemid 46606297)
10. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 11 2004 879 882 (Pubitemid 38807610)
11. L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, and J. Mackey Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 8 2003 1735 1744 (Pubitemid 37238631)
12. T. Saarto, C. Blomqvist, M. Valimaki, P. Makela, S. Sarna, and I. Elomaa Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antiestrogens Br J Cancer 75 4 1997 602 605 (Pubitemid 27085307)
13. J.R. Berenson, B.E. Hillner, R.A. Kyle, K. Anderson, A. Lipton, and G.C. Yee American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma J Clin Oncol 20 17 2002 3719 3736 (Pubitemid 34983232)
14. B.E. Hillner, J.N. Ingle, J.R. Berenson, N.A. Janjan, K.S. Albain, and A. Lipton American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 18 6 2000 1378 1391 (Pubitemid 30159858)
15. R.A. Kyle, G.C. Yee, M.R. Somerfield, P.J. Flynn, S. Halabi, and S. Jagannath American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 17 2007 2464 2472 (Pubitemid 46999218)
16. E. Terpos, O. Sezer, P.I. Croucher, R. Garcia-Sanz, M. Boccadoro, and J. San Miguel The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network Ann Oncol 20 8 2009 1303 1317
17. F. De Marinis, W. Eberhardt, P.G. Harper, B.M. Sureda, K. Nackaerts, and J.B. Soerensen Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel J Thorac Oncol 4 10 2009 1280 1288
18. M. Aapro, P.A. Abrahamsson, J.J. Body, R.E. Coleman, R. Colomer, and L. Costa Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 3 2008 420 432
19. J.J. Body, R. Coleman, P. Clezardin, C. Ripamonti, R. Rizzoli, and M. Aapro International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients Eur J Cancer 43 5 2007 852 858 (Pubitemid 46366687)
20. C.A. Migliorati, M.M. Schubert, D.E. Peterson, and L.M. Seneda Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy Cancer 104 1 2005 83 93 (Pubitemid 40847755)
21. A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, and A. Rapoport Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 6 2006 945 952 (Pubitemid 46638849)
22. A. Bamias, E. Kastritis, C. Bamia, L.A. Moulopoulos, I. Melakopoulos, and G. Bozas Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 34 2005 8580 8587 (Pubitemid 46211499)
23. E.P. Wang, L.B. Kaban, G.J. Strewler, N. Raje, and M.J. Troulis Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J Oral Maxillofac Surg 65 7 2007 1328 1331 (Pubitemid 46915477)
24. T. Van den Wyngaert Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates J Evid Based Dent Pract 7 3 2007 132 135
25. D. Henry, R. von Moos, S. Vadhan-Raj, V. Hungria, A. Spencer, and V. Hirsh A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma Eur J Cancer Suppl 7 3 2009 12
26. A. Stopeck, J.J. Body, Y. Fujiwara, A. Lipton, G.G. Steger, and M. Viniegra Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study Eur J Cancer Suppl 7 3 2009 2 3
27. S.B. Woo, J.W. Hellstein, and J.R. Kalmar Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 10 2006 753 761 (Pubitemid 46780635)
28. C.A. Migliorati, S.B. Woo, I. Hewson, A. Barasch, L.S. Elting, and F.K. Spijkervet A systematic review of bisphosphonate osteonecrosis (BON) in cancer Support Care Cancer 18 8 2010 1099 1106
29. M.R. Allen Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench Cells Tissues Organs 189 1-4 2009 289 294
30. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. Lda J 2005;64(3):21-4.
31. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-76.
32. S. Ruggiero, J. Gralow, R.E. Marx, A.O. Hoff, M.M. Schubert, and J.M. Huryn Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer J Oncol Pract 2 1 2006 7 14
33. R. Weitzman, N. Sauter, E.F. Eriksen, P.G. Tarassoff, L.V. Lacerna, and R. Dias Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006 Crit Rev Oncol Hematol 62 2 2007 148 152 (Pubitemid 46575276)
34. C.I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, and G. Saibene Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann Oncol 20 1 2009 137 145
35. M.A. Dimopoulos, E. Kastritis, C. Bamia, I. Melakopoulos, D. Gika, and M. Roussou Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 1 2009 117 120
36. V. Montefusco, F. Gay, F. Spina, M.T. Ambrosini, M. Maniezzo, and L. Farina Antibiotic prophylaxis before dental procedures can reduce ONJ incidence Blood (ASH Annual Meeting Abstracts) 110 11 2007 3613
37. V. Bocci Ozone as Janus: this controversial gas can be either toxic or medically useful Mediators Inflamm 13 1 2004 3 11 (Pubitemid 38621643)
38. A.S. Grigor'ian, L.A. Grigor'iants, and M.N. Guchetl Experimental- morphological study of the anti-inflammatory action of ozone-perfluorane complex application Stomatologiia (Mosk) 87 2 2008 4 9
39. A. Agrillo, M.T. Petrucci, M. Tedaldi, M.C. Mustazza, S.M. Marino, and C. Gallucci New therapeutic protocol in the treatment of avascular necrosis of the jaws J Craniofac Surg 17 6 2006 1080 1083 (Pubitemid 44934724)
40. A. Agrillo, P. Sassano, C. Rinna, P. Priore, and G. Iannetti Ozone therapy in extractive surgery on patients treated with bisphosphonates J Craniofac Surg 18 5 2007 1068 1070 (Pubitemid 47524913)
41. A. Agrillo, C. Ungari, F. Filiaci, P. Priore, and G. Iannetti Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis J Craniofac Surg 18 5 2007 1071 1075 (Pubitemid 47524914)
42. M.T. Petrucci, C. Gallucci, A. Agrillo, M.C. Mustazza, and R. Foa Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients Haematologica 92 9 2007 1289 1290 (Pubitemid 350144201)
43. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, and B. Mehrotra American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 5 Suppl 2009 2 12
44. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 1989 1 10 (Pubitemid 19099520)
45. E.N. Atkinson, and B.W. Brown Confidence limits for probability of response in multistage phase II clinical trials Biometrics 41 3 1985 741 744